

GILENYA[®] (fingolimod)


Important things for Patients, Parents and Caregivers to remember about GILENYA[®] (fingolimod) treatment

If you get any side effects, talk to your doctor, pharmacist or nurse. By reporting side effects, you can help provide more information on the safety of this medicine. You can report side effects directly via HPRA Pharmacovigilance, website: www.hpra.ie. Side effects could also be reported to Novartis preferably via www.report.novartis.com, or by email to drugsafety.dublin@novartis.com or by calling 01 2080 612.

Date approved by the HPRA: 21st October 2022



What is multiple sclerosis?




MS is a long-term condition that affects the central nervous system (CNS), comprised of the brain and spinal cord. In MS, inflammation destroys the protective sheath (called myelin) around the nerves in the CNS and stops the brain cells (neurons) from working properly. This is called demyelination.

Relapsing-remitting MS is characterised by repeated attacks (relapses) that reflect inflammation within the CNS. Symptoms vary from patient to patient. Symptoms of a relapse may disappear completely when the relapse is over, but some problems may remain.

How does GILENYA® work?

Your immune system normally fights infections to prevent illnesses. However, if you have MS it can become overactive and attack the myelin that protect the neurons and help them to carry messages from your brain to the rest of your body.



GILENYA® helps to protect against attacks on the CNS by the immune system by reducing the ability of some white blood cells (lymphocytes) to move freely within the body and by stopping them from reaching the brain and spinal cord. This can reduce the neural damage caused by MS.

Contraindications and precautions



The doctor will ask the person who has been prescribed GILENYA[®], to stay at the clinic for 6 hours or more after taking the first dose so that appropriate measures can be taken if side effects occur. In some circumstances, an overnight stay may be required. For paediatric patients similar precautions will be taken if their dose is increased from 0.25 mg to 0.5 mg once daily.



GILENYA[®] should not be used in patients with specific cardiac diseases, and is not recommended in patients who are also taking medicines that are known to decrease heart rate.



GILENYA[®] must not be used in women who are pregnant and women of child-bearing potential (including female adolescents) not using effective contraception.

If you are a woman of child-bearing potential or the parent/caregiver of a female adolescent of child-bearing potential prescribed GILENYA[®], you will be provided with a Pregnancy-Specific Patient Reminder Card.

Contraindications and precautions



Please read the Patient Information Leaflet thoroughly before you or the child/adolescent in your care starts treatment with GILENYA[®]. The Patient Information Leaflet should be retained so you can refer to it throughout treatment.



Please inform the doctor if the individual taking GILENYA[®] or anyone related to them, has a history of epilepsy.



Contact your doctor immediately if you or the child/adolescent in your care experiences any adverse reactions during treatment with GILENYA[®].

Any doctors that you or the child/adolescent in your care sees should be told they are taking GILENYA[®].



Before starting GILENYA® treatment

Pregnancy – GILENYA® can harm an unborn baby (the medicine is said to be ‘teratogenic’). Women of child-bearing potential (including female adolescents) should be informed by their doctor about GILENYA®’s serious risk to the unborn baby. Women of child-bearing potential (including female adolescents) must have a negative pregnancy test and be using effective contraception before starting treatment with GILENYA®.



Human papilloma virus (HPV)-related cancer – Your doctor will assess whether you need to undergo cancer screening (including a Pap test) and if you should receive the HPV vaccine.



Liver function – GILENYA® can cause abnormal results in liver function tests. You or the child/adolescent in your care will need a blood test prior to treatment initiation with GILENYA®.



Seizures – Seizures may occur during treatment. Inform your doctor if the individual taking GILENYA® or a family member have a history of epilepsy.

The first time you take GILENYA® (fingolimod)

Slow heart rate and irregular heartbeat – At the beginning of treatment, GILENYA® causes the heart rate to slow down. This may cause dizziness or lower the blood pressure. If the individual taking GILENYA® in your care experiences symptoms such as dizziness, nausea, vertigo, or palpitations or feel uncomfortable after taking the first dose of fingolimod, please immediately inform their doctor.



Before taking the first dose, you or the child/adolescent will have:

- A baseline electrocardiogram (ECG) to assess the action of their heart.
- A blood pressure measurement.
- Paediatric patients will also be weighed and measured, and will undergo a physical development assessment.

During the 6 hour monitoring:

- Pulse and blood pressure checked every hour – You or the child/adolescent may be monitored with a continuous ECG during this time
- An ECG at the end of 6 hours

It is important to ensure medication compliance and avoid misuse especially treatment interruption which may result in a requirement to repeat cardiac monitoring. Call the doctor in case of treatment interruption if you or the child/adolescent has stopped GILENYA® for at least:

- 1 day or more during first 2 weeks of treatment
- Or more than 7 days during weeks 3 and 4 of treatment
- Or more than 2 weeks after one month on treatment

as the initial effect on your heart rate may occur again. When GILENYA® therapy is restarted, the doctor may decide to repeat monitoring of heart rate and blood pressure measurements every hour, to run ECGs, and if needed, to monitor you or the child/adolescent overnight.

While you are taking GILENYA® (fingolimod)



Infections — Because GILENYA® affects the immune system, those treated with it are more likely to get infections. If the individual taking GILENYA® have any of the following, during and up to 2 months

after stopping treatment, call their doctor straight away: a headache accompanied by a stiff neck, sensitivity to light, fever, flu-like symptoms, nausea, rash, shingles and or/confusion or seizures (fits) (possible symptoms of meningitis and/or encephalitis, either caused by fungal or viral infection).

If you believe your MS or that of the child/adolescent in your care is getting worse (e.g. weakness or visual changes) or if you notice any new symptoms, talk to their doctor as soon as possible. These may be the symptoms of a rare brain disorder called progressive multifocal leukoencephalopathy (PML), which is caused by an infection.



Cancer — The doctor will assess whether any individuals taking GILENYA® needs to undergo cancer screening (including a Pap test), and if they should receive the human papilloma virus (HPV) vaccine.



Skin cancer — Skin cancers have been reported in MS patients treated with GILENYA®. Inform the doctor immediately if you notice any skin nodules (e.g. shiny pearly nodules), patches or open sores that do not heal

within weeks. Symptoms of skin cancer may include abnormal growth or changes in skin tissue (e.g. unusual moles) with a change in colour, shape or size over time.



Liver function — Some cases of acute liver failure requiring liver transplant and clinically significant liver injury have been reported. A blood test to assess liver function will be required prior to initiation and at months 1,3,6,9 and 12 during GILENYA[®] therapy and regularly thereafter until 2 months after GILENYA[®] discontinuation. Inform the doctor if you notice any yellowing of the skin or the whites of the eyes, abnormally dark urine, pain on the right side of the stomach area, tiredness, feeling less hungry than usual or unexplained nausea and vomiting as these can be signs of liver injury.



Pregnancy — Women of child-bearing potential (including female adolescents) should be provided with regular counselling about GILENYA[®]'s serious risks to an unborn baby by their doctor. Women of child-bearing potential (including female adolescents) must have a negative pregnancy test before starting treatment with GILENYA[®] and must use effective contraception while taking GILENYA[®] and for two months after stopping treatment, because

of the serious risks of GILENYA[®] to the unborn baby. In case of pregnancy (intended or unintended) during treatment, or in the 2 months after stopping treatment with GILENYA[®], the doctor should be informed straight away.



Visual symptoms — GILENYA[®] may cause swelling at the back of the eye, a condition that is known as macular oedema. Tell the doctor if you or the child/adolescent in your care experiences any changes in vision during and up to 2 months after stopping treatment.



Seizures — Seizures may occur during treatment. Inform the doctor if you or the child/adolescent in your care, or someone related to them, has a history of epilepsy.



Depression and anxiety — Both conditions have been reported in paediatric patients treated with GILENYA[®]. Talk to your doctor if you or the child/adolescents in your care are experiencing symptoms.



Stopping GILENYA[®] treatment may result in return of disease activity. The doctor will decide whether and how you or the child/adolescent needs to be monitored after stopping GILENYA[®].

Please see the *“Patient Information Leaflet”*
for more information.

IE_216822

Date of preparation: July 2022

Date approved by the HPRA: 21st October 2022

RMP: V19.1

